DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Ballock RT, O’Keefe RJ. The biology of the growth plate. J Bone
Joint Surg, 2003, 85-A:715–726.
Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by
PTN, vitamin D, and FGF 23. Annu Rev Med, 2010, 61:
91–104.
Bianco SD, Peng JB, Takanaga H, et al. Marked disturbance of
calcium homeostasis in mice with targeted disruption of the
Trpv6 calcium channel gene. J Bone Miner Res, 2007, 22:
274–285.
Bilezikian JP, Potts JT Jr, Fuleihan Gel H, et al. Summary statement
from a workshop on asymptomatic primary hyperparathyroidism:
A perspective for the 21st century. J Bone
Miner Res, 2002, 17 suppl 2:N2–N11.
Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, et al. Benefitrisk
assessment of vitamin D supplementation. Osteoporos Int,
2009 December 3 (Epub ahead of print).
Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate
after one year of parathyroid hormone (1-84) for
osteoporosis. N Engl J Med, 2005, 353:555–565.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic
acid for treatment of postmenopausal osteoporosis. N Engl J
Med, 2007, 356:1809–1822.
Bland R, Walker EA, Hughes SV, et al. Constitutive expression
of 25-hydroxyvitamin D 3
-1a-hydroxylase in a transformed
human proximal tubule cell line: Evidence for direct regulation
of vitamin D metabolism by calcium. Endocrinology, 1999,
140:2027–2034.
Bodnar LM, Simhan HN, Powers RW, et al. High prevalence of
vitamin D insufficiency in black and white pregnant women
residing in the northern United States and their neonates. J
Nutr, 2007, 137:447–452.
Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience
with alendronate for osteoporosis in postmenopausal
women. N Engl J Med, 2004, 350:1189–1199.
Carney SL. Calcitonin and human renal calcium and electrolyte
transport. Miner Electrolyte Metab, 1997, 23:43–47.
Carswell S. Vitamin D in the nervous system: Action and therapeutic
potential. In: Vitamin D. (Feldman D, Glorieux FH, Pike
JW, eds.), Academic Press, San Diego, 1997, pp. 1197–1212.
Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin
D concentrations and risk for hip fractures. Ann Intern Med,
2008, 149:242–250.
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus
progestin on risk of fracture and bone mineral density: The
Women’s Health Initiative randomized trial. JAMA, 2003, 290:
1729–1738.
Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized
trial of nasal spray salmon calcitonin in postmenopausal
women with established osteoporosis: The prevent recurrence
of osteoporotic fractures study. PROOF Study Group. Am J
Med, 2000, 109:267–276.
Clemett D, Spencer CM. Raloxifene: A review of its use in postmenopausal
osteoporosis. Drugs, 2000, 60:379–411.
Cosman F. Parathyroid hormone treatment for osteoporosis. Curr
Opin Endocrinol, Diabetes Obes, 2008, 15:495–501.
Costante G, Meringolo D, Durante C, et al. Predictive value of
serum calcitonin levels for preoperative diagnosis of medullary
thyroid carcinoma in a cohort of 5817 consecutive patients
with thyroid nodules. J Clin Endocrinol Metab, 2007,
92:450–455.
Cummings SR, McClung MR, Christiansen C, et al. A phase III
study of the effects of denosumab on vertebral, nonvertebral,
and hip fracture in women with osteoporosis: results from the
FREEDOM trail. J Bone Miner Res, 2008, 12:S80.
D’Amour P. Lessons from a second- and third-generation
parathyroid hormone assays in renal failure patients. J
Endocrinol Invest, 2008, 31:459–462.
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and
vitamin D supplementation on bone density in men and women
65 years of age or older. N Engl J Med, 1997, 337:670–676.
Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg
risedronate on 2 consecutive days a month: Efficacy and safety
results. Osteoporos Int, 2008, 19:1039–1045.
DeLuca HF. The vitamin D story: A collaborative effort of basic
science and clinical medicine. FASEB J, 1988, 2:224–236.
Drueke TB, Ritz E. Treatment of secondary hyperparathyroidism
in CKD patients with cinacalcet and/or vitamin D derivatives.
Clin J Am Soc Nephrol, 2009, 4:234–241.
Dunford JE, Thompson K, Coxon FP, et al. Structure-activity
relationships for inhibition of farnesyl diphosphate synthase
in vitro and inhibition of bone resorption in vivo by nitrogencontaining
bisphosphonates. J Pharmacol Exp Ther, 2001,
296:235–242.
Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance
and reporting oversight in US FDA fast-track process:
Bisphosphonates and osteonecrosis of the jaw. Lancet Oncol,
2008, 9:1166–1172.
Eknoyan G, Levin A, Levin NW. Bone metabolism and disease
in chronic kidney disease. Am J Kidney Dis, 2003, 42:1–201.
Elders PJ, Lips P, Netelenbos JC, et al. Long-term effect of calcium
supplementation on bone loss in perimenopausal women.
J Bone Miner Res, 1994, 9:963–970.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral
fracture risk in postmenopausal women with osteoporosis
treated with raloxifene: results from a 3-year randomized clinical
trial. Multiple Outcomes of Raloxifene Evaluation
(MORE) Investigators. JAMA, 1999, 282:637–645.
Evenepoel P. Calcimimetics in chronic kidney disease:
Evidence, opportunities and challenges. Kidney Int, 2008,
74:265–275.
Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of
parathyroid hormone, alendronate, or both in men with osteoporosis.
N Engl J Med, 2003, 349:1216–1226.
Franceschini N, Joy MS, Kshirsagar A. Cinacalcet HCl: A calcimimetic
agent for the management of primary and secondary
hyperparathyroidism. Expert Opin Investig Drugs, 2003,
12:1413–1421.
Friedman PA, Bushinsky DA. Diuretic effects on calcium metabolism.
Semin Nephrol, 1999, 19:551–556.
Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis
with high doses of synthetic calcitriol. A randomized
controlled study. Ann Intern Med, 1990, 113:649–655.
Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy
plus zoledronic acid in premenopausal breast cancer. N Engl J
Med, 2009, 360:679–691.
Gorn AH, Rudolph SM, Flannery MR, et al. Expression of two
human skeletal calcitonin receptor isoforms cloned from a
giant cell tumor of bone. The first intracellular domain modulates
ligand binding and signal transduction. J Clin Invest,
1995, 95:2680–2691.
1303
CHAPTER 44
AGENTS AFFECTING MINERAL ION HOMEOSTASIS AND BONE TURNOVER